TRADEMIT

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

Co	omplete if Known
Application Number	09/936,499
Filing Date	09/12/2001
First Named Inventor	Stephen B. Liggett
Art Unit	1634
Examiner Name	Goldberg
Attorney Docket Number	

			U.S. PATI	ENT DOCUMENTS	
Examiner Initials*		Document Number Number - Kind Code ² (if known,	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
00	AA		12/05/2000	Drazen et al.,	Entire Document
<u>U</u>		US-			
	_	US-			
		US-		. m	
		US-			
		US-			
		US-			ļ — · · · · · · · · · · · · · · · · · ·
		US-			

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code 3 -Number 4 -Kind Code 5 (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ.	
89	AB	wo 00/31307 A1	06/02/2000	Liggett, Stephen B.	Entire Document		
		·		1		-	
				\		_	
						_	
					······	t	

ĺ	Examiner	A Moodhola	Date	8/26/20
ţ	Signature	y solousing	Considered	126 03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). *2See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

DEC 1 2 2001 UNIVERSE SUDIN

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB shirt of number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 2 of 2

Complete if Known					
Application Number	Application Number 09/936,499				
Filing Date	09/12/2001				
First Named Inventor	Stephen B. Liggett				
Group Art Unit					
Examiner Name					
Attorney Docket Number	MWH-0031US				

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), litle of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
94	BA	GREEN, S.B. ET AL., "Influence of B2-Adrenergic Receptor Genotypes on Signal Transduction in Human Airway Smooth Muscle Cells," Am. J. Respir. Cell Mol. Biol., Vol. 13, p. 25-33, (1995).	
	BB	GREEN, S.B. ET Al., "Amino-Terminal Polymorphisms of the Human B2-Adrenergic Receptor Impart Distinct Agonist-Promoted Regulatory Properties," Biochemistry, Vol. 33, p. 9414-9419, (1994).	
	вс	GREEN, S.B. ET AL., "A Polymorphism of the Human B2-Adrenergic Receptor within the Fourth Transmembrane Domain Alters Ligand Binding and Functional Properties of the Receptor," The Journal of Biological Chemistry, Vol. 268, p.23116-21, (1993).	
	BD	HALL, IAN ET AL., "Association of Glu27 B2-Adrenoceptor Polymorphism with Lower Airway Reactivity in Asthmatic Subjects," The Lancet, Vol. 345, p. 1213-4, (1995).	:
-	BE	LIGGETT, S.B., "Functional Properties of Human B2-Adrenergic Receptor Polymorphisms," News in Physiological Sciences, Vol. 10, p. 265-273, (1995).	
	BF	LIGGETT, S.B., "The Genetics of B2-Adrenergic Receptor Polymorphisms: Relevance to Receptor Fuction and Asthmatic Phenotypes," The Genetics of Asthma, 1st ed., Marcel Dekker (New York), p. 455-478, (1996).	
	BG	LIGGETT, S.B. ET AL., "The Ile164 B2-Adrenergic Receptor Polymorphism Adversely Affects the Outcome of Congestive Heart Failure," J. Clin. Invest., Vol. 102 (No. 8), p. 1534-1539, (1998).	•
	вн	LIGGETT, S.B., "Polymorphisms in the 5' Leader Cistron of the B2-Adrenergic Receptor," Pending U.S. Application, Serial No.09/856,803, (Filed May 25, 2001).	Ì
	BI	MCGRAW, D.W. ET AL., "Polymorphisms in the 5' Leader Cistron of the Human B2-Adrenergic Receptor Regulate Receptor Expression," J. Clin, Invest., Vol. 102 (No. 11), p. 1927-1932, (1998).	
	вј	REIHSAUS, ELLEN ET AL., "Mutations in the Gene Encoding for the B2-Adrenergic Receptor In Normal and Asthmatic Subjects," Am. J. Respir. Cell Mol. Biol., Vol. 8, p. 334-339, (1993).	
	BK	TURKI, JAMAL ET AL., "Genetic Polymorphism of the B2-Adrenergic Receptor in Nocturnal and Nonnocturnal Asthma," J. Clin. Invest., p. 1635-1641, (1995).	

						-
Examiner		11-111-	•	Date	W1.	100
Signature	<u> </u>	splanding		Considered	४/३७/	03

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (02-03)

Approved for use through 04/30/2003, OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. MAR 1 3 2003 Substitute for form 1449/PTO Complete if Known **Application Number** 09/936,499 INFORMATION DISCLOSURE Filing Date Stephen B. Liggett Ap 1029 1634

Goldberg 1630

MWH-0031US 09/12/2001 STATEMENT BY APPLICANT First Named Inventor Art Unit (Use as many sheets as necessary) Examiner Name Sheet Attorney Docket Number of 1 1

			~
		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	0
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
84	CA	LIGGETT, S.B., "POLYMORPHISMS OF THE B2-ADRENERGIC RECEPTOR AND ASTHMA," Am J. Respir Crit Care Med., p. 5156-5162, (1997).	5
V	СВ	TAN, SOONG, ET AL., "Association Between B2-Adrenoceptor Polymorphisms and Susceptibility to Bronchodilator Desensitisation in Moderately Severe Stable Asthmatics," The Lancet, p. 995-999, (1997).	
		RECEIVE	
		RECEIVE MAR 2 1 2003 TECH CENTER 1600/29	D
		CENTER 1600/26	00
		·	

Examiner Signature Date Considered 8/ab/D3

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered. Include copy or tris form with next communication to applicant.

1 Applicant's unique citation designation number (optional).

2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office. U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.